SPIRITT: A Randomized, Multicenter, Phase II Study of Panitumumab with FOLFIRI and Bevacizumab with FOLFIRI as Second-Line Treatment in Patients with Unresectable Wild Type KRAS Metastatic Colorectal Cancer-Reference-Cited by-同舟云学术

SPIRITT: A Randomized, Multicenter, Phase II Study of Panitumumab with FOLFIRI and Bevacizumab with FOLFIRI as Second-Line Treatment in Patients with Unresectable Wild Type KRAS Metastatic Colorectal Cancer

Published:2015-06 Issue:2 Volume:14 Page:72-80
ISSN:1533-0028
Container-title:Clinical Colorectal Cancer
language:en
Short-container-title:Clinical Colorectal Cancer

Author:

Hecht J. Randolph,Cohn Allen,Dakhil Shaker,Saleh Mansoor,Piperdi Bilal,Cline-Burkhardt Mika,Tian Ying,Go William Y.

Funder

Amgen

Publisher

Elsevier BV

Subject

Gastroenterology,Oncology

Reference25 articles.

1. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group;Saltz;N Engl J Med,2000

2. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer;de Gramont;J Clin Oncol,2000

3. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer;Hurwitz;N Engl J Med,2004

4. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer;Cunningham;N Engl J Med,2004

5. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer;Van Cutsem;N Engl J Med,2009

Cited by 103 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world outcomes of FOLFOXIRI plus bevacizumab in patients with metastatic colorectal cancer: the JSCCR-TRIPON study;International Journal of Clinical Oncology;2024-08-28

2. Comparison of systemic treatments for previously treated patients with unresectable colorectal liver metastases: a systematic review and network meta-analysis;Frontiers in Oncology;2024-07-10

3. Colon Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology;Journal of the National Comprehensive Cancer Network;2024-06

4. Impact of Systemic Treatments on Outcomes and Quality of Life in Patients with RAS-Positive Stage IV Colorectal Cancer: A Systematic Review;Diseases;2024-04-20

5. Fruquintinib as new treatment option in metastatic colorectal cancer patients: is there an optimal sequence?;Expert Opinion on Pharmacotherapy;2024-03-03